Multiplexed Quantification of Nucleic Acids with Large Dynamic

Range Using Multivolume Digital RT-PCR on a Rotational SlipChip Tested with HIV and Hepatitis C Viral Load by Shen, Feng et al.
S1 
Multiplexed quantification of nucleic acids with 
large dynamic range using multivolume digital 
RT-PCR on a rotational SlipChip tested with HIV 
and Hepatitis C viral load  
Feng Shena†, Bing Suna, Jason E. Kreutza, Elena K. Davydovaa, Wenbin Dua‡, Poluru L. 
Reddyb, Loren J. Josephb, Rustem F. Ismagilova&*  
a. Department of Chemistry and Institute for Biophysical Dynamics, The University of 
Chicago, 929 East. 57th St., Chicago, Illinois 60637 
b. Department of Pathology, University of Chicago Medical Center, 5481 S. Maryland Ave, 
Chicago, IL 60637 
†Current Address: SlipChip, LLC, 2201 Campbell Park Drive, Chicago, IL, 60612 
‡Current Address: Department of Chemistry, Renmin University of China, Beijing, China, 
100872 
&Current Address: Division of Chemistry and Chemical Engineering, California Institute of 
Technology, 1200 E. California Blvd, Pasadena, CA 91125. 
S2 
Experimental section  
Chemicals and Materials 
All solvents and salts obtained from commercial sources were used as received unless 
otherwise stated. SsoFast EvaGreen SuperMix (2X) was purchased from Bio-Rad 
Laboratories (Hercules, CA). One-Step SuperScript® III Reverse Transcriptase, iPrepTM 
purification instrument, and iPrepTM PureLinkTM virus kit were purchased from Invitrogen 
Corporation (Carlsbad, CA). All primers were purchased from Integrated DNA Technologies 
(Coralville, IA). Bovine serum albumin (20 mg/mL) was ordered from Roche Diagnostics 
(Indianapolis, IN). Mineral oil, tetradecane, and DEPC-treated nuclease-free water were 
purchased from Fisher Scientific (Hanover Park, IL). Dichlorodimethylsilane was ordered 
from Sigma-Aldrich (St. Louis, MO). PCR Mastercycler and in situ adapter were purchased 
from Eppendorf (Hamburg, Germany). Spectrum food color was purchased from August 
Thomsen Corp (Glen Cove, NY). Soda-lime glass plates coated with layers of chromium and 
photoresist were ordered from Telic Company (Valencia, CA). Photomasks were designed 
using AutoCAD (San Rafael, CA) and ordered from CAD/Art Services, Inc. (Bandon, OR). 
MicropositTM MFTM-CD-26 developer was purchased from Rohm and Hass Electronic 
Materials LLC (Marlborough, MA). Amorphous diamond coated drill bits were purchased 
from Harvey Tool (0.030 inch cutter diameter, Rowley, MA). Adhesive PDMS film (0.063 
inch thick) was purchased from McMaster (Atlanta, GA). The MinElute PCR purification kit 
and QIAamp Viral RNA mini kit were purchased from Qiagen Inc. (Valencia, CA). The 
OptiQuant®-S HCV RNA quantification panel was purchased from AcroMetrix (Benicia, 
CA).  
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Fabrication of SlipChip for multivolume digital RT-PCR 
The procedure for fabricating the SlipChip from soda lime glass was based on the 
procedure described in previous work.1,2 To fabricate SlipChip for multivolume digital 
RT-PCR, wells of two different depths were etched using a two-step exposing-etching 
protocol. The soda lime glass plate pre-coated with chromium and photoresist was first 
aligned with a photomask containing the design for wells of 25 nL and 125 nL for Design 1 
(Table 1). For Design 2, this photomask also contained the designs of the additional wells of 
625 nL. The glass plate was then exposed to UV light using standard exposure protocols. 
After exposure, the glass plate was detached from the photomask and immersed in developer 
to immediately remove the photoresist that was exposed to UV light. The underlying 
chromium layer that was exposed was removed by applying a chromium etchant (a solution 
of 0.6:0.365 mol/L HClO4 / (NH4)2Ce(NO3)6). The glass plate was thoroughly rinsed with 
water and dried with nitrogen gas. The glass plate was then aligned with a second photomask 
containing the designs of wells of 1 nL and 5 nL for Design 1 (Table 1) by using a mask 
aligner. For Design 2, this second photomask also contained the designs of the additional 
wells of 0.2 nL. The glass plate was then exposed to UV light a second time. After the 
second exposure, the photomask was detached from the glass plate, and the back side of the 
glass plate was protected with PVC sealing tape. The taped glass plate was then immersed in 
a glass etching solution (1:0.5:0.75 mol/L HF/NH4F/HNO3) to etch the glass surface where 
chromium coating was removed in the previous step (areas containing wells of 25 nL, 125 
nL, and 625 nL), and the etching depth was measured by a profilometer. After the larger 
features were etched to a depth of 70 µm, the glass plate was placed in the developer again to 
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remove the previously exposed photoresist in areas containing the patterns for the smaller 
features (1 nL and 5 nL wells, and the additional wells of 0.2 nL for Design 2). The 
underlying chromium layer was removed by using the chromium etchant as describe above, 
and a second glass etching step was performed to etch all features to a further depth of 30 
µm. The final SlipChip contained wells of depths of 100 µm and 30 µm was fabricated. 
After the two-step etching, the glass plate was thoroughly rinsed with Millipore water 
and ethanol and then dried with nitrogen gas. The glass plate was oxidized using a plasma 
cleaner and immediately placed in a desicator with dichlorodimethylsilane for gas-phase 
silanization. For Design 2A, circular inlet reservoirs (4 mm inner diameter and 6 mm outer 
diameter) were made by cutting adhesive PDMS film, then fixing the reservoirs around the 
five inlets before plasma cleaning. After one hour, the silanized glass plate was thoroughly 
rinsed with chloroform, acetone, and ethanol, and then dried with nitrogen gas.  
To re-use the glass SlipChips, each SlipChip was thoroughly cleaned with piranha acid 
(3:1 sulfuric acid: hydrogen peroxide), then oxidized using a plasma cleaner and silanized as 
described above. 
Assembling the SlipChip 
The SlipChip was assembled under de-gassed oil (mineral oil: tetradecane 1:4 v/v). The 
bottom plate was immersed into the oil phase with the patterned wells facing up, and the top 
plate was then immersed into the oil phase and placed on top of the bottom plate with the 
patterned side facing down. The two plates were aligned under a stereoscope (Leica, 
Germany) as shown in Figure 1A and stabilized using binder clips. 
Loading the SlipChip 
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A through-hole was drilled in the center of the top plate to serve as the solution inlet for 
Design 1 and Design 2B. The reagent solution was loaded through the inlet by pipetting. For 
Design 2A, five through-holes were drilled at the top left corner of the top plate to serve as 
fluid inlets (Figure 5A). For multiplex experiments, five different reaction solutions were 
placed in the inlet reservoirs, and a dead-end filling adapter was placed on top of the 
SlipChip to cover all the inlets. A pressure of 18 mmHg was applied to load all the solutions 
simultaneously. The principle and detailed method for dead-end filling are described in a 
previous work.3 Reservoirs were removed after the solution was loaded.  
Synthesis and purification of control RNA (906nt) 
The control RNA (906 nucleotide) was synthesized from the LITMUS 28iMal Control 
Plasmid using a HiScribe™ T7 In Vitro Transcription Kit with the manufacture’s 
recommended procedures (New England Biolabs, Ipswich, MA) and purified using MinElute 
PCR purification kit with manufacture recommended protocols.  
Automatic Viral RNA purification from plasma sample  
Plasma samples containing the HIV virus were obtained from deidentified patients at the 
University of Chicago Hospital. Plasma containing a modified HCV virus as a control (25 
million IU/mL, part of OptiQuant-S HCV Quantification Panel) was purchased from 
AcroMetrix (Benicia, CA). A plasma sample of 400 µL was mixed with 400 µL lysis buffer 
(Invitrogen Corporation, Carlsbad, CA) to lyse the virus. Then 2 µL of control RNA (906 nt) 
was added to characterize the purification efficiency and concentrating factor. The mixed 
sample was then transferred into the iPrepTM PureLinkTM virus cartridge. The cartridge was 
placed in the iPrepTM purification instrument and the purification protocol was performed 
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according to the manufacturer’s instructions. The final elution volume was 50 µL, therefore 
a theoretical eight-fold concentrating factor was expected. The initial concentration of 
control RNA and the concentration of control RNA in the purified sample after preparation 
were characterized on the SlipChip (Design 1). The final concentrating factor was 4.5 for 
HCV and 6.6 for HIV in the multiplex RT-PCR amplification (Figure 5). The concentrating 
factors for the two HIV samples were 7.1 and 6.6 for the experiments in Figure 6.  
Primer sequences for RT-PCR amplification  
Primers for the control RNA (906 nt) were: GAA GAG TTG GCG AAA GAT CCA CG 
and CGA GCT CGA ATT AGT CTG CGC. The control RNA template was serially diluted in 
1 mg/mL BSA solution. The RT-PCR mix contained the following: 30 µL of 2 × EvaGreen 
SuperMix, 1 µL of each primer (10 µmol/L), 3 µL of BSA solution (20 mg/mL), 1.5 µL of 
SuperScript® III Reverse Transcriptase, 17.5 µL of nuclease-free water, and 6 µL of 
template solution. 
Primer sequences for HIV viral RNA was selected from a previous publication:4 GRA 
ACC CAC TGC TTA ASS CTC AA; GAG GGA TCT CTA GNY ACC AGA GT.  
Primer sequences for control HCV viral RNA were selected from a previous publication:5 
GAG TAG TGT TGG GTC GCG AA; GTG CAC GGT CTA CGA GAC CTC.  
RT-PCR amplification on the SlipChip 
To amplify HIV viral RNA in Figure 5, the RT-PCR mix contained the following: 15 µL 
of 2 × EvaGreen SuperMix, 0.6 µL of each primer (10 µmol/L), 1.5 µL of BSA solution (20 
mg/mL), 0.75 µL of SuperScript® III Reverse Transcriptase, 10.05 µL of nuclease-free water, 
and 1.5 µL of template solution. The template solution used here was diluted 250-fold from 
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the original HIV viral RNA stock solution purified from Patient sample 2 using 1 mg/mL 
BSA solution.  
To amplify control HCV viral RNA in Figure 5, the RT-PCR mix contained the 
following: 15 µL of 2 × EvaGreen SuperMix, 0.25 µL of each primer (10 µmol/L), 1.5 µL of 
BSA solution (20 mg/mL), 0.75 µL of SuperScript® III Reverse Transcriptase, 10.25 µL of 
nuclease-free water, and 2 µL of template solution. The template solution was diluted 5-fold 
from the original control HCV viral RNA stock solution purified from OptiQuant-S HCV 
Quantification Panel.  
To amplify the control RNA (906 nt) in Figure 5, the RT-PCR mix contained the 
following: 15 µL of 2 × EvaGreen SuperMix, 0.25 µL of each primer (10 µmol/L), 1.5 µL of 
BSA solution (20 mg/mL), 0.75 µL of SuperScript® III Reverse Transcriptase, 10.25 µL of 
nuclease-free water, and 2 µL of template solution. The template solution was diluted 5-fold 
from the original control HCV viral RNA stock solution purified from OptiQuant-S HCV 
Quantification Panel.  
The experiment in Figure 5 was repeated six times and all the data was used to calculate 
the target concentration.    
To amplify HIV viral RNA with expected final concentration above 1000 molecules/mL 
in the RT-PCR mix in Figure 6, the RT-PCR mix contained the following: 20 µL of 2 × 
EvaGreen SuperMix, 1 µL of each primer (10 µmol/L), 2 µL of BSA solution (20 mg/mL), 1 
µL of SuperScript® III Reverse Transcriptase, 13 µL of nuclease-free water, and 2 µL of 
template solution. The template was serially diluted in 1 mg/mL BSA solution. For 
experiments with HIV viral RNA concentration below 1000 molecules/mL in the final 
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RT-PCR mix, the RT-PCR mix contained the following: 30 µL of 2 × EvaGreen SuperMix, 
1.5 µL of each primer (10 µmol/L), 2 µL of BSA solution (20 mg/mL), 1.5 µL of 
SuperScript® III Reverse Transcriptase, 3.5 µL of nuclease-free water, and 20 µL of 
template solution.  
To amplify the control RNA (906 nt) in the HIV sample in Figure 5 and Figure 6, the 
RT-PCR mix contained the following: 20 µL of 2 × EvaGreen SuperMix, 1 µL of each 
primer (10 µmol/L), 2 µL of BSA solution (20 mg/mL), 1 µL of SuperScript® III Reverse 
Transcriptase, 13 µL of nuclease-free water, and 2 µL of HIV viral RNA stock solution after 
sample preparation. 
The concentration of control RNA (906 nt) before sample preparation was characterized 
on SlipChip Design 1 with the RT-PCR mix contained the following: 20 µL of 2 × EvaGreen 
SuperMix, 1 µL of each primer (10 µmol/L), 2 µL of BSA solution (20 mg/mL), 1 µL of 
SuperScript® III Reverse Transcriptase, 13 µL of nuclease-free water, and 2 µL of template 
solution. The template was prepared by diluting 2 µL of stock control RNA (906nt) solution 
into 400 µL of 1 mg/mL BSA solution. 
To amplify HIV viral RNA in Figure S1, the RT-PCR mix for HIV viral RNA contained 
the following: 90 µL of 2 × EvaGreen SuperMix, 3.6 µL of each primer (10 µmol/L), 6 µL 
of BSA solution (20 mg/mL), 4.5 µL of SuperScript® III Reverse Transcriptase, 12.3 µL of 
nuclease-free water, and 60 µL of template solution. The template solution used here was 
diluted 62500-fold from the original HIV viral RNA stock solution purified from Patient 
sample 2 using 1 mg/mL BSA solution. This experiment was repeated six times and all data 
was used to calculate HIV viral RNA concentration. Three negative control experiments 
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were performed with the same primer pairs but no HIV viral RNA, and showed no false 
positives.  
 The amplifications were performed using a PCR mastercycler machine (Eppendorf). To 
amplify the RNA, an initial 30 min at 50 °C was applied for reverse transcription, then 2 min 
at 95 °C for enzyme activation, followed by 35 cycles of 1 min at 95 °C, 30 sec at 55 °C and 
45 sec at 72 °C. After the final cycle, a final elongation step was applied for 5 min at 72 °C. 
This thermal cycling program was applied to all experiments except for those in Figure S1, 
where 39 cycles were adapted instead of 35 cycles. 
Image acquisition and analysis 
Bright-field images in Figure 1 and Figure 5 were acquired using a Canon EOS Rebel 
XS digital SLR camera (Lake Success, NY). Other bright-field images were acquired using a 
Leica stereoscope. All fluorescence images were acquired by Leica DMI 6000 B 
epi-fluorescence microscope with a 5X / 0.15 NA objective and L5 filter at room 
temperature. All fluorescence images were corrected for background by using an image 
acquired with a standard fluorescent control slide. All the images were then stitched together 
using MetaMorph software (Molecular Devices, Sunnyvale, CA). 
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Figure S1. Representative experiment performing RT-PCR of HIV viral RNA at an expected 
concentration of 51 molecules/mL in RT-PCR mix on the Design 2B SlipChip to test the 
lower detection limit of the device. This experiment was repeated six times to quantify the 
viral RNA concentration. 
 
 
Figure S2. Representative negative control for HIV viral load (HIV primers with no loaded 
HIV RNA template) on SlipChip Design 1, corresponding to experiments shown in Figure 6. 
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Table S1. Performance of quantification of HIV viral RNA concentration from patient 1 on 
SlipChip comparing to Roche COBAS® AmpliPrep / COBAS® TaqMan® HIV-1 Test, v2.0 
system (CAP/CTM v2.0). Each experiment was repeated at least four times on SlipChip. 
Only 2 significant digits are shown. The expected HIV concentration of patient plasma was 
calculated based on dilution factors and a single result from Roche CAP/CTM v2.0. The 
results from SlipChip are obtained with serial diluted purified patient HIV viral RNA and are 
converted to the original concentration in patient plasma (with or without dilutions) using the 
purification concentrating factor. 
Dilution 
Factor 
Expected p HIV viral 
RNA concentration 
based on a Roche 
CAP/CTM v2.0 test 
(molecules/mL) 
Average of calculated HIV 
viral RNA concentration 
based on experiments on 
SlipChip (molecules/mL) 
Standard deviation of 
calculated HIV viral RNA 
concentration based on 
experiments on SlipChip 
(molecules/mL) 
1 2.3 × 105 1.6 × 105 1.3 × 104 
1:10 2.3 × 104 1.3 × 104 3.0 × 103 
1:100 2.3 × 103 1.4 × 103 6.5 × 102 
1:1000 2.3 × 102 93 32 
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Table S2. Performance of quantification of HIV viral RNA concentration from patient 2 on 
SlipChip comparing to Roche COBAS® AmpliPrep / COBAS® TaqMan® HIV-1 Test, v2.0 
system (CAP/CTM v2.0). Each experiment was repeated at least four times on SlipChip. 
Only 2 significant digits are shown. The expected HIV concentration of patient plasma was 
calculated based on dilution factors and a single result from Roche CAP/CTM v2.0. The 
results from SlipChip are obtained with serial diluted purified patient HIV viral RNA and are 
converted to the original concentration in patient plasma (with or without dilutions) using the 
purification concentrating factor. 
 
Dilution 
Factor 
Expected p HIV viral RNA 
concentration based on a 
Roche CAP/CTM v2.0 test 
(molecules/mL) 
Average of calculated HIV 
viral RNA concentration 
based on experiments on 
SlipChip (molecules/mL) 
Standard deviation of 
calculated HIV viral RNA 
concentration based on 
experiments on SlipChip 
(molecules/mL) 
1 1.5 × 106 1.7 × 106 3.9 × 105 
1:20 7.3 × 104 9.2 × 104 4.0 × 104 
1:400 3.6 × 103 3.3 × 103 6.3 × 102 
1:8000 1.8 × 102 1.8 × 102 81 
1:40000 36 37 37 
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